Evidence map›Paper›PMID 38750400›Full record

ArticleThe AAPS journal2024

Impact on Quality during In-Use Preparation of an Antibody Drug Conjugate with Eight Different Closed System Transfer Device Brands.

Léa Sorret, Wei Han Tan, Senta Voss, Patrick Favrod, Pascal Chalus, Matthias Winzer

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Léa SorretLonza AG, Drug Product Services, Hochbergerstrasse 60G, 4057, Basel, Switzerland. lea.sorret@lonza.com.ORCID http://orcid.org/0009-0007-5138-1041
Wei Han TanLonza AG, Drug Product Services, Hochbergerstrasse 60G, 4057, Basel, Switzerland.
Senta VossMerck Healthcare KGaA, 64293, Darmstadt, Germany.
Patrick FavrodLonza AG, Drug Product Services, Hochbergerstrasse 60G, 4057, Basel, Switzerland.
Pascal ChalusLonza AG, Drug Product Services, Hochbergerstrasse 60G, 4057, Basel, Switzerland.
Matthias WinzerMerck Healthcare KGaA, 64293, Darmstadt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate the in-use compatibility of eight commercially available closed system transfer device brands (CSTDs) with a formulated model antibody drug conjugate (ADC). Overall, in-use simulated dosing preparation applying the CSTD systems investigated raised concerns for several product quality attributes. The incompatibilities observed were mainly associated with increased visible and subvisible particles formation as well as significant changes in holdup volumes. Visible and subvisible particles contained heterogeneous mixtures of particle classes, with the majority of subvisible particles associated with silicone oil leaching from CSTD systems during simulated dose preparation upon contact with the ADC formulation. These observations demonstrate that CSTD use may adversely impact product quality and delivered dose which could potentially lead to safety and efficacy concerns during administration. Other product quality attributes measured including turbidity, color, ADC recovery, and purity by size exclusion HPLC, did not show relevant changes. It is therefore strongly recommended to test and screen the compatibility of CSTDs with the respective ADC, in a representative in-use simulated administration setting, during early CMC development, i.e., well before the start of clinical studies, to include information about compatibility and to ensure that the CSTD listed in the manuals of preparation for clinical handling has been thoroughly assessed before human use.

Indexed as

ImmunoconjugatesChemistry, PharmaceuticalDrug CompoundingParticle SizeImmunoconjugatesAntibody drug conjugate (ADC)Closed System Transfer Device (CSTD)Hazardous drugs (HD)In-use dose preparationMaterial of construction (MoC)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.